Alkermes (NASDAQ:ALKS) Announces Earnings Results, Beats Expectations By $0.11 EPS

Alkermes (NASDAQ:ALKS - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.11, Zacks reports. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. Alkermes updated its FY 2025 guidance to 1.030-1.210 EPS.

Alkermes Trading Down 0.3 %

ALKS traded down $0.11 on Friday, hitting $35.89. The company had a trading volume of 2,626,767 shares, compared to its average volume of 1,335,446. Alkermes has a 1 year low of $22.90 and a 1 year high of $36.25. The firm has a market cap of $5.81 billion, a P/E ratio of 18.41, a PEG ratio of 1.83 and a beta of 0.49. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. The company's fifty day moving average price is $30.40 and its 200 day moving average price is $28.80.

Analysts Set New Price Targets

ALKS has been the topic of several research reports. Stifel Nicolaus upgraded shares of Alkermes from a "hold" rating to a "buy" rating and upped their price target for the stock from $25.00 to $36.00 in a research report on Tuesday, November 5th. The Goldman Sachs Group lifted their price target on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Friday. Deutsche Bank Aktiengesellschaft initiated coverage on Alkermes in a research report on Tuesday, February 11th. They issued a "buy" rating and a $40.00 price objective on the stock. Cantor Fitzgerald dropped their target price on Alkermes from $48.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, October 25th. Finally, Piper Sandler restated an "overweight" rating and issued a $37.00 price target (down from $38.00) on shares of Alkermes in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $37.25.

Insider Buying and Selling at Alkermes

In other news, Director Cato T. Laurencin sold 2,691 shares of Alkermes stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total transaction of $85,708.35. Following the transaction, the director now owns 23,013 shares in the company, valued at approximately $732,964.05. The trade was a 10.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Christian Todd Nichols sold 5,208 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the transaction, the senior vice president now directly owns 60,703 shares of the company's stock, valued at approximately $1,769,492.45. This trade represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 323,608 shares of company stock worth $10,854,725. 4.89% of the stock is owned by insiders.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.